Physician profile
Ross Sweet
NPI 1114972890
$528.84
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $73.93 · 2021: $224.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $369.43 | 2019-2021 | |
| Pfizer INC. | $45.16 | 2019 | |
| Rochester Medical Corporation | $35.64 | 2020-2021 | |
| Boston Scientific Corporation | $24.63 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $21.12 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $17.93 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.